Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)

News
Video

Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.

Related Videos
A panel of 5 experts on lung cancer seated at a long table
A panel of 5 experts on lung cancer seated at a long table
Jason Porter, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Hope Rugo, MD, an expert on breast cancer, presenting slides
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Related Content
Lyudmila A. Bazhenova, MD

Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC

November 30th 2023
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
Biagio Ricciuti, MD

Long-Term Survival Benefit With PD-1 Monotherapy Correlated With High PD-L1 Expression in Advanced NSCLC

November 29th 2023
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
Yu Wang, MD, PhD, chief medical officer of GenFleet

IBI351 NDA Under NMPA Review in Advanced KRAS G12C–Mutant NSCLC

November 28th 2023
Article
Konstantinos Arnaoutakis, MD

Increasingly Specialized Clinical Trials Accelerate Advances in NSCLC Management

November 27th 2023
Article